HOME >> BIOLOGY >> NEWS
TIGR and NIAID sign $65 million microbial sequencing contract

Rockville, MD Oct. 2, 2003 - The world's leading center for microbial genomics, The Institute for Genomic Research (TIGR), has signed a five-year, $65 million contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to sequence and analyze the genomes of pathogenic microbes and invertebrate vectors of infectious diseases for the wider scientific community.

Under the contract, TIGR will sequence dozens of genomes per year. Among the organisms to be considered for sequencing will be pathogenic microorganisms and invertebrate vectors of infectious diseases. "We look forward to working in partnership with NIAID to help meet the needs of the infectious disease research community for genomic data and analysis," said TIGR President Claire M. Fraser, Ph.D.

TIGR's affiliated sequencing facility, the J. Craig Venter Science Foundation Joint Technology Center, also located in Rockville, MD, will conduct the sequencing under the contract, with TIGR investigators leading each genome project and coordinating the analysis. The Joint Technology Center, which began operations this summer, is one of the world's largest and most technologically advanced sequencing centers.

TIGR, a not-for-profit research institute, sequenced the first genome of a free-living organism in 1995. Since then, TIGR has sequenced the genomes of more than 50 other organisms or microbial strains, including the genomes of microbes that cause pneumonia, cholera, syphilis, anthrax, malaria, meningitis, Lyme disease, and gingivitis.

Fraser said the sequencing accomplished under the NIAID contract will provide invaluable data to the international community of scientists who study the microorganisms that cause infectious diseases and seek to develop more effective treatments and vaccines. Whole-genome analyses of several pathogens have led to vaccine and antimicrobial drug development projects.

"TIGR has set
'"/>

Contact: Robert Koenig
rkoenig@tigr.org
301-838-5880
The Institute for Genomic Research
2-Oct-2003


Page: 1 2

Related biology news :

1. NIAID unveils bioterrorism research agenda
2. NIAID takes next genome step
3. NIAID awards grant to rapidly sequence the malaria mosquito genome
4. NIAID launches major step in trial of experimental shingles vaccine
5. NIAID-Supported Scientists Discover Origin Of HIV-1
6. NIAID Scientists Discover HIV Disease-Slowing Mutation
7. NIAID Doctor Successfully Treats Longest Case Of Malaria Infection On Record
8. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
9. Half-million dollar landmark achieved for the Methuselah Mouse Prize
10. HHMI, NIBIB/NIH to invest up to $35 million in interdisciplinary Ph.D. programs
11. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: TIGR and NIAID sign million microbial sequencing contract

(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/25/2015)... 26, 2015 Agnition announced today that ... American Farmer, airing for the first time at 7:30 ... American Farmer will explore the extremely important role soil ... with a patented Microbial Catalyst™ technology that enhances soil ... The segment will air again on April 28. , ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Laboratory ... Top-Loading Balances and Analytical Balances to get best-performing ... line of weighing balances from the trusted brand ... Balances increase your efficiency by providing a ... of samples. Weighing modes include parts counting, percent ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: